ArticleBMC cancer2025
Analysis of the immune microenvironment in colorectal cancer with different KRAS gene subtypes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer.Cancers · 2026Article
- Article
- Integrative transcriptomic profiling of tumor patients in surgical ICU: identifying prognostic immune signatures.Frontiers in molecular biosciences · 2026Article
- Integrated multi-omics characterization of SPTBN2 overexpression reveals its pro-tumorigenic role and immune microenvironment remodeling in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
- Comprehensive analysis of KLHL35 expression and its prognostic value in cancer: implications for colorectal cancer diagnosis and therapy.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo explore the differences in tumor immune microenvironment between different KRAS mutation subtypes, and to provide a new direction for clinical immunotherapy of different subtypes of colorectal cancer.
methodsWe examined the spatial distribution of common inflammatory cell markers of CD8 + T cells, CD4 + T cells, natural killer cells, and B cells and macrophages in 55 colorectal cancer patients with different KRAS gene phenotypes using immunohistochemistry and panoramic scanning. We analyzed the relationship between inflammatory cells and clinical information. TCGA and String online databases were used to analyze the relationship between KRAS mutation subtypes and inflammatory cell markers.
resultsWe observed that significant differences in the spatial distribution of the tumor invasion front and the immune cell infiltration within the tumor. Colorectal cancer patients with different KRAS mutations showed different immune infiltration, and the main cells with differences were FOXP3 regulatory T cells and M2 macrophages. Furthermore, these two cell types were strongly associated with the prognosis of KRAS wild-type and KRAS mutant colorectal cancer.
conclusionsThe complexity of the immune microenvironment cannot be explained by infiltration of specific cell types alone, but may arise from cell-to-cell interactions or changes in the proportion of different immune cells. However, the infiltration of FOXP3 cells and M2 macrophages probably accounts for the differences between KRAS mutant subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.